About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Two New Cholera Vaccines Developed

by Sheela Philomena on October 26, 2013 at 11:08 AM
 Two New Cholera Vaccines Developed

Cuban researchers are working on developing two new cholera oral-vaccines, say experts.

Reinaldo Acevedo, deputy director of Cuba's Finlay Institute, told the 20th Latin American Pharmacology and Therapeutics Congress that the institute is working on a live vaccine and an inactive one, Xinhua reported Thursday.

Advertisement

The live vaccine, in development for more than 10 years, "is composed of live cholera bacteria after extracting the virulence factors. Thus, it is a strain of the disease, but is not pathogenic," Acevedo said.

The vaccine elicits "an immune response" but patients won't get sick, he said.

Compared with other existing vaccines worldwide, the Cuban version has the advantage of being administered in a single oral dose which eliminates the virus in less than 72 hours, he said.
Advertisement

The live vaccine is still under development stage, but has been tested in Cuba and Mozambique with good results in both safety and effectiveness. "New clinical trials in children are likely later this year," he added.

Cholera, an acute diarrhoea disease, causes 100,000 to 120,000 deaths each year worldwide, according to the Pan American Health Organization (PAHO). Cuba witnessed a cholera outbreak in 2012.

The Finlay Institute is also developing an inactive vaccine, composed of dead micro-organisms which is much cheaper to develop, said Sonsire Castillo, deputy director of the institute.

"Live vaccines usually require abundant resources, technologies, and logistics for production," she added.

Additionally, with live vaccines, "there is also the fear that they may affect immunologically compromised patients, such as those with AIDS," she said.

Source: IANS
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Two New Cholera Vaccines Developed Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests